J Rheumatol:银屑病患者心血管危险因素诊断和治疗的差距

2018-02-09 xiangting MedSci原创

很大比例的银屑病和PsA患者的高血压和血脂异常存在漏诊和治疗不足。

这项研究旨在评估在一个国际性多中心银屑病和银屑病关节炎(PsA)患者队列中心血管危险因素(CVRF)漏诊和治疗不足的比例。

研究人员对来自国际银屑病与关节炎研究组队列的银屑病患者进行了横断面分析。确定了是否有可改变的CVRF(糖尿病高血压(HTN),血脂异常,吸烟,体重指数升高和中心性肥胖)以及是否对HTN和血脂异常使用适当治疗方法。根据Framingham风险评分计算10年CV风险。评估了医生对血脂异常和HTN治疗指南的依从性。使用回归分析来评估HTN和血脂异常治疗不足的预测指标。

纳入加拿大、美国和以色列8个中心共2254例患者(PsA占58.9%,银屑病占41.1%)。平均年龄52±13.8岁,男性占53%。其中87.6%至少有1个可改变CVRF,45.1%有HTN,49.4%血脂异常,13.3%糖尿病,75.3%超重或肥胖,54.3%中心性肥胖,17.3%目前吸烟。研究人员发现59.2%高血压患者和65.6%血脂异常患者存在治疗不足。治疗不足与年龄较小(≤50岁)、银屑病和男性相关。

在现实环境中,很大比例的银屑病和PsA患者的高血压和血脂异常存在漏诊和治疗不足。下一步需要改善银屑病患者CVRF管理的策略。

原始出处:

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1948922, encodeId=43db1948922c5, content=<a href='/topic/show?id=1e4789584b0' target=_blank style='color:#2F92EE;'>#血管危险因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89584, encryptionId=1e4789584b0, topicName=血管危险因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Sun Feb 11 02:06:00 CST 2018, time=2018-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1331484, encodeId=95b4133148426, content=<a href='/topic/show?id=afab51e831d' target=_blank style='color:#2F92EE;'>#心血管危险因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51783, encryptionId=afab51e831d, topicName=心血管危险因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bb182500058, createdName=yuhaisheng_ibp_32061711, createdTime=Sun Feb 11 07:06:00 CST 2018, time=2018-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1629770, encodeId=ef081629e7046, content=<a href='/topic/show?id=28c351e80dc' target=_blank style='color:#2F92EE;'>#心血管危险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51780, encryptionId=28c351e80dc, topicName=心血管危险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3e0221357465, createdName=lingaifan, createdTime=Sun Feb 11 07:06:00 CST 2018, time=2018-02-11, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1948922, encodeId=43db1948922c5, content=<a href='/topic/show?id=1e4789584b0' target=_blank style='color:#2F92EE;'>#血管危险因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89584, encryptionId=1e4789584b0, topicName=血管危险因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Sun Feb 11 02:06:00 CST 2018, time=2018-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1331484, encodeId=95b4133148426, content=<a href='/topic/show?id=afab51e831d' target=_blank style='color:#2F92EE;'>#心血管危险因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51783, encryptionId=afab51e831d, topicName=心血管危险因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bb182500058, createdName=yuhaisheng_ibp_32061711, createdTime=Sun Feb 11 07:06:00 CST 2018, time=2018-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1629770, encodeId=ef081629e7046, content=<a href='/topic/show?id=28c351e80dc' target=_blank style='color:#2F92EE;'>#心血管危险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51780, encryptionId=28c351e80dc, topicName=心血管危险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3e0221357465, createdName=lingaifan, createdTime=Sun Feb 11 07:06:00 CST 2018, time=2018-02-11, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1948922, encodeId=43db1948922c5, content=<a href='/topic/show?id=1e4789584b0' target=_blank style='color:#2F92EE;'>#血管危险因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89584, encryptionId=1e4789584b0, topicName=血管危险因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Sun Feb 11 02:06:00 CST 2018, time=2018-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1331484, encodeId=95b4133148426, content=<a href='/topic/show?id=afab51e831d' target=_blank style='color:#2F92EE;'>#心血管危险因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51783, encryptionId=afab51e831d, topicName=心血管危险因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bb182500058, createdName=yuhaisheng_ibp_32061711, createdTime=Sun Feb 11 07:06:00 CST 2018, time=2018-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1629770, encodeId=ef081629e7046, content=<a href='/topic/show?id=28c351e80dc' target=_blank style='color:#2F92EE;'>#心血管危险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51780, encryptionId=28c351e80dc, topicName=心血管危险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3e0221357465, createdName=lingaifan, createdTime=Sun Feb 11 07:06:00 CST 2018, time=2018-02-11, status=1, ipAttribution=)]

相关资讯

DRUGS:Guselkumab获得首次全球认证

近日,美国强生研发的Guselkumab(Tremfya)已经获得美国FDA的上市审核用以治疗块型银屑病和银屑病型关节炎。和传统靶向TNF的抗炎抗体相比,Guselkumab特异性地作用于全新靶点白细胞介素(IL)-23。IL-23在辅助性T 细胞17(Th-17)的分化和增殖以及由其产生的包括IL-17和IL-22在内的促炎性细胞因子中起着关键作用。Th-17 / IL-17通路在抵御细菌和真菌

J Am Acad Dermatol:虽然蕈样肉芽肿和银屑病患者静脉血栓栓塞的**风险较小,但其相对风险不能忽视

背景:蕈样肉芽肿(Mycosis fungoides,MF),本病又名蕈样霉菌病,是起源于记忆性辅助T细胞的低度恶性的皮肤T细胞淋巴瘤,约占所有皮肤T细胞淋巴瘤的50%。病程呈慢性渐进性,初期为多种形态的红斑和浸润性损害,以后发展成肿瘤,晚期可累及淋巴结和内脏。蕈样肉芽肿和银屑病的特点均是恶性增生和慢性炎症,它们可能会影响静脉血栓栓塞(VTE)的风险。目标:本研究旨在MF和银屑病患者中评估VTE的

Curr Opin Immunol:研究确定牛皮癣发病新机制,这缠人的疾病可能有救了!

发表于《Current Opinion in Immunology》杂志上的一项研究提出了一种新的观点,银屑病和特应性皮炎(AD)来自同一种谱,不是单独的疾病,这一发现有望带来更好的理解和更好的治疗。

银屑病合并大疱性类天疱疮继发卡波西肉瘤一例

患者40余年前患有银屑病,2年前出现红斑水疱,确诊为大疱性类天疱疮。